On May 20, 2021, Merck announced V114, the company�s investigational 15-valent pneumococcal conjugate vaccine, met its primary immunogenicity and safety endpoints in two trials of the V114 Phase 3 pediatric clinical program.

These data support the potential use of V114 in healthy infants who may have previously started a pneumococcal vaccination series with the currently available 13-valent pneumococcal conjugate vaccine (PCV13) (PNEU-DIRECTION), and in a catch-up setting for healthy children who were either pneumococcal vaccine-na�ve or who previously received a full or partial regimen with lower valency pediatric pneumococcal conjugate vaccines (PNEU-PLAN).